• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system

tetano

Editor, Senior Moderator
Microbiol Immunol. 2013 Jul 4. doi: 10.1111/1348-0421.12079. [Epub ahead of print]
Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.
Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH.
Source

Department of Biotechnology, The Catholic University of Korea, Bucheon, 420-743, Republic of Korea.
Abstract

Although most of the influenza vaccines are produced in egg, new types of vaccines must be developed. We compared the immunogenicity and safety of a baculovirus-expressed hemagglutinin (HA) of H1N1 influenza virus (Korea/01/2009; designated "HA-Bac-K") with those of a commercially available baculovirus-expressed HA (designated "HA-Bac-C") and an Escherichia coli-expressed HA (designated "HA-E.Coli-K"). HA-Bac-K effectively induced hemagglutination inhibition (HI) and neutralization (NT) antibodies in mouse and ferret models. The different immunogenicities observed may be attributable to the different expression systems and purification protocols used. Our work suggests that HA expressed in a baculovirus system is an effective and safe candidate influenza vaccine.

This article is protected by copyright. All rights reserved.
KEYWORDS:

hemagglutinin, influenzavirus, vaccine

PMID:
23822120
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23822120
 
Back
Top Bottom